Cellectis S.A. (NASDAQ:CLLS) is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CLLS to report 3Q20 loss of $ 0.61 per share.
For the full year, analysts anticipate top line of $ 82.82 million, while looking forward to loss of $ 1.5 per share bottom line.
Previous Quarter Performance
Cellectis S.A. outlined loss for the second quarter of $ 0.68 per share, from the revenue of $ 4.62 million. The consensus estimates are loss of $ 0.74 per share from $ 5.01 million in revenue. The bottom line results beat street analysts by $ 0.06 or 8.11 percent, at the same time, top line results fell short of analysts by $ 0.39 million or 7.78 percent.
Stock Performance
Shares of Cellectis S.A. traded up $ 0.61 or 3.84 percent on Wednesday, reaching $ 16.50 with volume of 204.50 thousand shares. Cellectis S.A. has traded high as $ 16.84 and has cracked $ 16.06 on the downward trend
The closing price of $ 16.50, representing a 117.08 % increase from the 52 week low of $ 7.32 and a 29.63 % decrease over the 52 week high of $ 22.58.
The company has a market capital of $ 721.05 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th October 2020, downgraded by Robert W. Baird to Neutral from Outperform rating.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
